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LEfTER TO THE EDITOR
Mitotane in adrenocortical carcinoma
Sir - We read with interest the report of Haak et al. (1994)
regarding treatment of adrenocortical carcinoma with
mitotane and agree with the authors' conclusion thit
.adjuvant mitotate does not influence survival of patients.' As
the authors point out, several groups, including our own
(Venkatesh et al., 1989), have recommended further study of
the potential efficacy of mitotane in the adjuvant setting
based on outcome trends and theoretical considerations
derived from retrospective analyses of clinical data of
patients with adrenocortical cancer. We have recently
reported the outcome of 19 patients with regional disease
who were treated at the M.D. Anderson Cancer Center
between 1988 and 1991 and who had no evidence of residual
disease after primary surgery (Vassilopoulou-Sellin et al.,
1993). In our study, neither disease freedom nor survival was
favourably influenced by adjuvant mitotane; although not
statistically different, both disease-free interval and survival
were shortest in the treated group. In our experience, it was
extremely difficult for these patients (without evidence of
measurable disease) to tolerate more than 2 g day-' after the
first few months. While mitotane remains an effective tool for
the management of patients with metastatic or unresectable
disease, it is difficult to recommend its use in the adjuvant
setting.
Yours etc,
Rena Vassilopoulou-Sellin
Vicent F. Guinee
The University of Texas M.O.
Anderson Cancer Center
1515 Holcombe Boulevard,
Houston,
Texas 77030, USA
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